Case Series Analyses of the Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab
Latest Information Update: 04 Jul 2022
At a glance
- Drugs Nivolumab (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 28 Jun 2022 Status changed from active, no longer recruiting to completed.
- 08 Aug 2016 New trial record